Zymeworks Inc. announced upcoming investor conference participation focused on its novel biotherapeutics for difficult-to-treat diseases.
Quiver AI Summary
Zymeworks Inc., a clinical-stage biotechnology company focused on developing novel biotherapeutics for challenging diseases such as cancer, inflammation, and autoimmune conditions, announced its participation in several upcoming investor conferences. Management will engage in one-on-one meetings at Citi’s Biopharma Back to School Conference on September 3, followed by the Wells Fargo Healthcare Conference on September 4, the Cantor Global Healthcare Conference on September 5, and the Morgan Stanley Annual Global Healthcare Conference on September 8, all taking place in Boston and New York. Zymeworks is committed to advancing its pipeline, which includes zanidatamab, a bispecific antibody for HER2-positive biliary tract cancer that has garnered various regulatory approvals. The company continues to progress its clinical studies and leverages partnerships to enhance its therapeutic platforms.
Potential Positives
- Participation in multiple high-profile investor conferences highlights Zymeworks' commitment to engaging with the investment community and promoting its innovative pipeline.
- Accelerated approval of zanidatamab by the U.S. FDA signifies regulatory confidence in Zymeworks' product, positioning the company as a leader in biotherapeutics for cancer treatment.
- Zanidatamab's status as the first dual HER2-targeted bispecific antibody approved for its indication underscores the company's pioneering role in addressing unmet medical needs in oncology.
- The ongoing recruitment for Phase 1 studies of ZW171 and ZW191, along with plans for ZW251 to enter clinical trials, demonstrate Zymeworks' strong pipeline and future growth potential in biopharmaceuticals.
Potential Negatives
- Management's participation in multiple investor conferences could indicate a need for increased investor communication, potentially implying recent challenges in investor confidence or interest.
- Zanidatamab's reliance on conditional approvals and partnerships may raise concerns about the long-term viability and commercial success of the product without fully established market presence.
- The fact that Zymeworks is still in clinical stages for its product candidates may indicate a slower pathway to revenue generation compared to competitors with more advanced or commercialized products.
FAQ
What upcoming investor conferences will Zymeworks participate in?
Zymeworks will participate in the Citi, Wells Fargo, Cantor Global, and Morgan Stanley healthcare conferences from September 3 to 8, 2025.
What is Zymeworks known for?
Zymeworks is a biotechnology company focusing on developing novel biotherapeutics for difficult-to-treat diseases like cancer and autoimmune disorders.
What is zanidatamab?
Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks, approved for treating HER2-positive biliary tract cancer.
Where has zanidatamab received approval?
Zanidatamab has received accelerated approval in the U.S., conditional approval in China, and conditional marketing authorization in Europe.
What is Zymeworks' mission?
Zymeworks' mission is to make a significant difference for patients with difficult-to-treat conditions, including cancer, inflammation, and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 20 times in the past 6 months. Of those trades, 20 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 20 purchases buying 2,163,747 shares for an estimated $26,071,310 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 89 institutional investors add shares of $ZYME stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 5,710,840 shares (+33.1%) to their portfolio in Q2 2025, for an estimated $71,671,042
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,420,432 shares (-36.6%) from their portfolio in Q2 2025, for an estimated $17,826,421
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 766,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,625,147
- VANGUARD GROUP INC added 697,652 shares (+39.5%) to their portfolio in Q2 2025, for an estimated $8,755,532
- VESTAL POINT CAPITAL, LP added 650,000 shares (+130.0%) to their portfolio in Q2 2025, for an estimated $8,157,500
- REDMILE GROUP, LLC removed 638,318 shares (-13.3%) from their portfolio in Q2 2025, for an estimated $8,010,890
- PERCEPTIVE ADVISORS LLC removed 589,398 shares (-31.6%) from their portfolio in Q2 2025, for an estimated $7,396,944
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 08/11/2025
- TD Securities issued a "Buy" rating on 05/20/2025
- LifeSci Capital issued a "Outperform" rating on 03/11/2025
To track analyst ratings and price targets for $ZYME, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 3 analysts offer price targets for $ZYME in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $22.0 on 08/11/2025
- Robert Burns from HC Wainwright & Co. set a target price of $13.0 on 07/03/2025
- An analyst from LifeSci Capital set a target price of $30.0 on 03/11/2025
Full Release
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
- Citi’s Biopharma Back to School Conference: Zymeworks’ management will participate in one-on-one meetings on September 3 in Boston, MA.
- Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 4 at 4:30 pm Eastern Time (ET) in Boston, MA.
- Cantor Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 5 at 8:35 am ET in New York, NY.
- Morgan Stanley Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 8 at 3:20 pm ET in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting, and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]
Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
